Ventricular septal defects (VSDs) are the commonest heart malformations and may affect the membranous or the muscular septum. Clinical presentation depends on the amount of interventricular flow, which is determined by the size of the defect and the relative resistances of the pulmonary and systemic vascular beds. The prevalence of VSD is estimated at about 5% among infants. Many small malformations present at birth may later undergo spontaneous closure. VSD may have autosomal dominant or autosomal recessive inheritance and may exist as isolated forms or as part of a syndrome. This Utility Gene Test was developed on the basis of an analysis of the literature and existing diagnostic protocols. It is useful for confirming diagnosis, as well as for differential diagnosis, couple risk assessment and access to clinical trials.
General information about the disease
Ventricular septal defects (VSDs) are the commonest congenital cardiac malformations. They may exist in isolated form or in combination with other anomalies, such as part of tetralogy of Fallot, or with double outlet right ventricle or common arterial trunk (1) .
According to Soto et al. these malformations can be divided into membranous and muscular septal defects. The membranous septum is smaller than the muscular septum and is located at the base of the heart, below the right and noncoronary cusps of the aortic valve, between the inlet and outlet components of the muscular septum. The muscular septum is a nonplanar structure consisting of inlet, trabecular and infundibular components (2, 3) .
The pathogenesis of VSD primarily depends on the amount and direction of interventricular shunting and volume loading of the heart chambers. Prolapse of the aortic valve and obstruction of the pulmonary or systemic outflow tract are considered to be secondary effects (4) .
The manifestation of clinical symptoms is directly linked to the entity of interventricular flow, which is determined by the size of the defect and the relative resistances of the pulmonary and systemic vascular beds (4) .
The prevalence of VSD is estimated at about 5% among infants. Many small malformations present at birth may later undergo spontaneous closure. Patients with medium and larger VSDs can undergo to severe complications such as arrhythmias, pulmonary arterial hypertension, ventricular dysfunction, congestive heart failure or develop Eisenmenger syndrome (3, 5) .
Du et al. reported a high prevalence of VSD (56.6/1000 live births) among preterm neonates (6) . This defect is the commonest congenital malformation of the heart at one week of age and in the first three decades of life: 32.1% of all patients with congenital heart disease have ventricular septal defects (7). (27) , GDF3 (OMIM gene 606522) (28) , HIRA (OMIM gene 600237) (29) , GNB1L (OMIM gene 610778) (29) , and TUBA8 (OMIM gene 605742) (29) .
The vast majority of these genes are key components of the Nodal signaling pathway that is important for specification and patterning of vertebrate embryos (30) and in mammalian cardiac development (31) .
Pathogenic variants may include missense, nonsense, splicing, small insertions/deletions, small indels, gross deletions/insertions and regulatory substitutions.
Aims of the test
• To determine the gene defect responsible for the disease;
• To confirm clinical diagnosis;
• To assess the recurrence risk and perform genetic counselling for at-risk/affected individuals.
Test characteristics Specialist centers/ Published Guidelines
Guidelines for clinical use of the test are described in Genetics Home Reference (ghr.nlm.nih.gov) and Gene Reviews (32).
Test strategy
Clinically distinguishable syndromes can be analyzed by sequencing only those genes known to be associated with that specific disease using Sanger or Next Generation Sequencing (NGS); if the results are negative, or more generally if clinical signs are ambiguous for diagnosis, a multi-gene NGS panel is used to detect nucleotide variations in coding exons and flanking introns of the above genes. Potentially causative variants and regions with low coverage are Sanger-sequenced. Sanger sequencing is also used for family segregation studies.
Multiplex Ligation Probe Amplification (MLPA) is used to detect duplications and deletions in CRELD1, EVC, EVC2, GATA4, MLL2, NKX2-5 and TBX5.
To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml peripheral blood in a sterile tube with 0.5 ml K 3 EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated.
Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.
Genetic test results

Positive
Identification of pathogenic variants in the aforementioned genes confirms the clinical diagnosis and is an indication for family studies.
A pathogenic variant is known to be causative for a given genetic disorder based on previous reports or predicted to be causative based on the loss of protein function or expected significant damage to protein or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.
Inconclusive
Detection of a variant of unknown or uncertain significance (VUS): a new variation without any evident pathogenic significance or a known variation with insufficient evidence (or with conflicting evidence) to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives to assess variant segregation and clarify its contribution. In some cases, it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:
• alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments; • sequence variations in gene regions not investigated by this test, such as regulatory regions (5' and 3' UTR) and deep intronic regions; • variations in other genes not investigated by the present test.
Unexpected
Unexpected results may come out from the test, for example information regarding consanguinity; absence of family correlation or the possibility of developing genetically based diseases.
Risk for progeny
If the identified pathogenic variant has autosomal dominant transmission, the probability that an affected carrier transmit the disease variant to his/her children is 50% in any pregnancy, irrespective of the sex of the child conceived. In autosomal recessive mutations, both parents are usually healthy carriers. In this case, the probability of transmitting the disorder to the offspring is 25% in any pregnancy of the couple, irrespective of the sex of the child. An affected individual generates healthy carrier sons and daughters in all cases, except in pregnancies with a healthy carrier partner. In these cases, the risk of an affected son or daughter is 50%. Clinical sensitivity (proportion of positive tests if the disease is present) and clinical specificity (proportion of negative tests if the disease is not present)
Limits of the test
Clinical sensitivity: variations in the aforementioned genes are linked to VSD, but may be individual variations (identified in one or a few families) and total epidemiological data is therefore not available. Clinical sensitivity will be estimated based on internal cases.
Clinical specificity: is estimated at approximately 99% (33) .
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for VSD; b) the sensitivity of the test is greater than or equal to that of tests described in the literature.
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis Yes
Differential diagnosis Yes
Couple risk assessment Yes
Availability of clinical trials can be checked on-line at https://clinicaltrials.gov/
